High expression of thymosin beta 10 predicts poor prognosis for hepatocellular carcinoma after hepatectomy
- PDF / 1,264,787 Bytes
- 10 Pages / 595.276 x 793.701 pts Page_size
- 91 Downloads / 179 Views
WORLD JOURNAL OF SURGICAL ONCOLOGY
RESEARCH
Open Access
High expression of thymosin beta 10 predicts poor prognosis for hepatocellular carcinoma after hepatectomy Haoyuan Wang1,2†, Shanshan Jiang2†, Yaojun Zhang1,2, Ke Pan2, Jianchuan Xia2* and Minshan Chen1,2*
Abstract Background: Thymosin beta 10 (Tbeta10) overexpression has been reported in a variety of human cancers. However, the role of Tbeta10 in hepatocellular carcinoma (HCC) remains unclear. The aim of the present study was to analyze Tbeta10 expression in tumor and matched non-tumorous tissues, and to assess its prognostic significance for HCC after hepatectomy. Methods: The level of Tbeta10 mRNA and protein in tumor and matched non-tumorous tissues was evaluated in 26 fresh HCC cases by reverse transcription-polymerase chain reaction (RT-PCR) and western blot. Additionally, Tbeta10 protein expression in 196 HCC was analyzed by immunohistochemistry (IHC) and correlated with clinicopathological characteristics and survival. Results: Results from RT-PCR and western blot analysis show that the levels of Tbeta10 mRNA and protein were significantly higher in tumor tissues of HCC, compared to that in matched non-tumorous tissues (P = 0.01 and P 25 ng/ml
135
52
83
Absent
55
25
30
Present
141
57
84
0.161
Liver cirrhosis
Patients and tumor tissue samples
To detect the mRNA and protein level of Tbeta10 in HCC, fresh tumor and the matched adjacent nontumorous tissues were collected from 26 patients with HCC who underwent hepatectomy between October 2012 and December 2012 in our department, the Department of Hepatobiliary Surgery, Cancer Center of Sun Yat-Sen University (Guangzhou, China). A cohort of 196 consecutive patients who received hepatectomy for HCC in our department from January 2004 to December 2006 was enrolled. The including criteria for the present study were (1) no previous treatment for HCC before surgery, (2) histologic confirmation of HCC, (3) R0 resection, (4) no lymph node or extrahepatic metastasis, and (5) a follow-up period of ≥3.0 months. The main clinical and pathological variables of all patients were described in detail in Table 1. In brief, there were 162 male and 34 female patients, with a median age of 47-years old (mean ± SD: 47.1 ± 12.3, range: 15 to 78). Tumor size ranged from 1.3 cm to 24.0 cm (mean ± SD: 7.3 ± 4.0), 80 patients (40.8%) had a tumor ≤5.0 cm, and 116 (59.2%) had a tumor >5.0 cm. A total of 163 patients (83.2%) had a single tumor, and 33 (16.8%) had 2 to 3 tumors. Of the cohort, 173 patients (88.3%) had hepatitis B virus (HBV) infection, and only 2 patients had hepatitis C virus (HCV) infection. According to the 7th edition tumornode-metastasis (TNM) classification of the American Joint Committee on Cancer (AJCC) [14], 129 patients (65.8%) had stage I disease, 17 (8.7%) had stage II disease, and 50 (25.5%) had stage III disease (Table 1). RNA preparation and protein extraction
Total RNA was extracted by using Trizol solution (Invitrogen, Shanghai, China) according to manufacturer
0.521
Tumor size (c
Data Loading...
